- Home
- AADI vs SYRS Comparison
AADI vs SYRS Comparison
Compare AADI & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AADI
- SYRS
- Stock Information
- Founded
- AADI 2011
- SYRS 2011
- Country
- AADI United States
- SYRS United States
- Employees
- AADI N/A
- SYRS N/A
- Industry
- AADI Biotechnology: Pharmaceutical Preparations
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- AADI Health Care
- SYRS Health Care
- Exchange
- AADI Nasdaq
- SYRS Nasdaq
- Market Cap
- AADI 49.0M
- SYRS 52.5M
- IPO Year
- AADI N/A
- SYRS 2016
- Fundamental
- Price
- AADI $2.11
- SYRS $0.26
- Analyst Decision
- AADI Hold
- SYRS Hold
- Analyst Count
- AADI 3
- SYRS 5
- Target Price
- AADI $1.75
- SYRS $3.00
- AVG Volume (30 Days)
- AADI 114.7K
- SYRS 4.1M
- Earning Date
- AADI 11-06-2024
- SYRS 10-31-2024
- Dividend Yield
- AADI N/A
- SYRS N/A
- EPS Growth
- AADI N/A
- SYRS N/A
- EPS
- AADI N/A
- SYRS N/A
- Revenue
- AADI $25,070,000.00
- SYRS $386,000.00
- Revenue This Year
- AADI $8.10
- SYRS N/A
- Revenue Next Year
- AADI $8.54
- SYRS $1,011.11
- P/E Ratio
- AADI N/A
- SYRS N/A
- Revenue Growth
- AADI 7.80
- SYRS N/A
- 52 Week Low
- AADI $1.21
- SYRS $0.25
- 52 Week High
- AADI $5.70
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- AADI 56.23
- SYRS 27.55
- Support Level
- AADI $1.98
- SYRS $2.41
- Resistance Level
- AADI $2.40
- SYRS $3.40
- Average True Range (ATR)
- AADI 0.11
- SYRS 0.30
- MACD
- AADI 0.01
- SYRS -0.26
- Stochastic Oscillator
- AADI 36.96
- SYRS 0.33
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.